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Enterovirus 71 (EV71) causes severe neurological diseases resulting in high mortality in young children worldwide.
Development of an effective vaccine against EV71 infection is hampered by the lack of appropriate animal models
for efficacy testing of candidate vaccines. Previously, we have successfully tested the immunogenicity and
protectiveness of a candidate EV71 vaccine, containing recombinant Newcastle disease virus capsids that display an
EV71 VP1 fragment (NPt-VP11-100) protein, in a mouse model of EV71 infection. A drawback of this system is its
limited window of EV71 susceptibility period, 2 weeks after birth, leading to restricted options in the evaluation of
optimal dosing regimens. To address this issue, we have assessed the NPt-VP11-100 candidate vaccine in a hamster
system, which offers a 4-week susceptibility period to EV71 infection. Results obtained showed that the NPt-VP11-100
candidate vaccine stimulated excellent humoral immune response in the hamsters. Despite the high level of
antibody production, they failed to neutralize EV71 viruses or protect vaccinated hamsters in viral challenge studies.
Nevertheless, these findings have contributed towards a better understanding of the NPt-VP11-100 recombinant
protein as a candidate vaccine in an alternative animal model system.
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The virion protein 1 (VP1) of EV71 was widely used in
vaccine development using different delivery systems and
shown to confer protection against lethal EV71 infection
in mice [1,2]. The N-terminal portion of the VP1 protein
was suggested to contain a major antigenic site [3]. It also
preferentially bound by high-titered neutralizing anti-
bodies to EV71 in human cord sera [4]. Antigenic and
neutralization determinants, which are important for
vaccine development, are thus likely to be located in this
region. Sivasamugham and colleagues (2006) developed
and studied the first 100 amino acid residues of this
N-terminal region of VP1 by fusing it to a carrier protein,
a truncated nucleoprotein (NP) of Newcastle disease
virus (NDV). This protein construct was designated* Correspondence: nshafee@biotech.upm.edu.my
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reproduction in any medium, provided the oras NPt-VP11-100 and found to be highly immunogenic
in rabbit. The construct was also able to self-
assemble into ring-like particles that could increase
the VP11-100 immunogenicity. Rabbit sera generated
after immunization was shown to recognize and react
with the authentic EV71 [3]. Altogether, these data sug-
gest that the recombinant protein has great potential as a
promising vaccine candidate against EV71 infections.
Recently, a mouse model with a prolonged susceptibility
period to EV71 infections has been developed by Ong and
colleagues [5]. The susceptibility period was found to be
up to 2-weeks after birth. This well-characterized mouse
model infected by a mouse-adapted EV71 strain P5
(EV71P5) shared many characteristics with the human cen-
tral nervous system (CNS) disease. To test the protective
efficacy of the NPt-VP11-100 in this mouse model, we ini-
tially tested its immunogenicity in mice. It was found to
be a potent immunogen in adult mice [6]. Based on these
information, we performed an extensive viral challenge
studies in the above newborn mouse model. Newborntd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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40 % increase in survival rate compared to the control
group [7]. Interestingly, 50 % of these mice fully recov-
ered from their paralysis. Further analyses to improve
the protective efficacy of the NPt-VP11-100 were ham-
pered by the fact that the newborn mouse model can
only provide a 2-week susceptibility period to EV71
infections [5]. This narrow time window led to limitations
in the testing of various parameters for vaccination and
viral challenge. Previous study suggested that intervals be-
tween doses, age at priming and at the last dose of vaccin-
ation are factors that influence infant antibody responses
[8]. To address this issue, we needed an animal model
which can offer a prolonged susceptibility period. It was
observed that in newborn hamsters, EV71 virus was able
to cause symptomatic infection for up to 4 weeks after
birth (Prof. K.T. Wong, personal communication). Previ-
ously, Syrian hamsters were used to study Bulgarian
strains of EV71 [9]. The virus caused poliomyelitis-like
lesions in their central nervous system, myositis and par-
alysis. In the present study, we evaluated the immunogen-
icity and protective efficacy of the EV71 NPt-VP11-100
candidate vaccine in a Syrian hamster model which offers
a prolonged period of susceptibility to EV71 infection.
Initially, the full length NP (NPfl) and NPt-VP11-100
recombinant proteins were induced and purified as
described previously [6,7]. The EV71P5 was obtained
from the Department of Pathology, Faculty of Medicine,
Universiti Malaya, Malaysia [5]. Purified VP1 protein of
Enterovirus 71 was kindly provided by Prof. M.J.
Cardosa of the Institute of Health and Community
Medicine, Universiti Malaysia Sarawak [4].
Pregnant Syrian hamsters were purchased from the
Animal House, Universiti Kebangsaan Malaysia. Ani-
mal experiments were done according to The Univer-
siti Putra Malaysia Animal Care and Use Committee
guidelines (AUP No: 10R84) and animals were cared
for in accordance with The Code to Care and Use of
Animals in Research. Newborn hamsters were immu-
nized with three doses (10 μg per dose) of either NPfl
(control group; n = 4) or NPt-VP11-100 (n = 5) proteins
at 1-, 6- and 13-day old. The first dose containing
50 % Freund’s adjuvant (Sigma, USA) was injected sub-
cutaneously, and subsequent doses containing Freund’s
incomplete adjuvant (Sigma, USA) were injected intra-
peritoneally. On day 28 after birth, all the hamsters were
challenged intraperitoneally with 2.53 x 106 TCID50 of
EV71P5 virus. This viral dose was 4 times higher than
the dose used in the mouse model study [7]. Their body
weight and paralysis score were monitored and recorded
daily until day 12 post-challenge. The paralysis score
was defined as: score 0, no hind limb paralysis and
healthy; score 1, mild paralysis, weakness in hind limb
(s); score 2, moderate paralysis, jerky movement; score3, a hind limb shows severe paralysis; score 4, both hind
limbs show severe paralysis. Their survival rate was
monitored until the end of the experiment on day 18
post-challenge when they were sacrificed via cardiac
puncture to collect their sera for further analysis. All
the collected sera were subjected to an indirect enzyme-
linked immunosorbent assay (ELISA) and immunoblot-
ting analysis against purified full length VP1 and NPfl
proteins as described previously [6,7].
To test for potential EV71 neutralization properties of
the antibodies produced, the sera were mixed with an
equal volume of 100 TCID50 EV71 strain A104 virus and
incubated at 37°C for 2 h. The resulting mixtures were
assayed on Vero cells seeded in a 96-well plate as
described in Ch'ng et al. [7]. Cytopathic effects (CPE) were
examined after 7 days of incubation and neutralization
titers were determined as the highest dilutions that
resulted in a 50 % inhibition of CPE. All the experimental
data in this study were analysed using the Student's t-test
and presented as mean± standard error (SE). Differences
with p <0.05 were considered significant.
Following purification, the NPfl and NPt-VP11-100
proteins appeared as distinct bands on Coomassie Brilliant
Blue-stained 12 % SDS-PAGE gel. As expected, the NPfl
and NPt-VP11-100 proteins showed an approximate mo-
lecular weight of 55 and 60 kDa, respectively (Figure 1A).
Band patterns obtained were similar to our previous
reports [3,6,7]. The purified proteins were then used to
vaccinate newborn hamsters as described above. Upon
challenge with EV71P5, the hamsters in both groups
showed mild or moderate paralysis symptoms (Figure 1B).
The NPt-VP11-100-immunized group, however, showed
lower paralysis score compared to the control group
(Figure 1C). This lower score correlated with their higher
overall weight gain (Figure 1D). These results suggest that
even though EV71P5 is a mouse-adapted strain [5], it is
still capable of infecting hamsters and produce symptoms
similar to the ones observed in mice [7], although at a
lower severity. In the mice study, we managed to give only
2 doses of vaccination prior to virus challenge due to the
2-week susceptibility period of the mice to EV71 infection.
In the present study, we gave 3 doses of vaccination
to the hamsters. Despite the increase in dosages and
immunization period, the NPt-VP11-100-immunized ham-
sters failed to display any protection from the EV71P5
challenge. Even though they displayed symptoms of EV71
infection, all hamsters including the NPfl control group,
survived until the end of experiment. Their body weight
increased gradually and their symptoms did not change
significantly until the end of the experiment. This is in
contrast to the findings obtained from the mouse model
study [7]. In that study, a 40% survival rate was observed
in the NPt-VP11-100-immunized mice while 100% mortal-
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Figure 1 Protein production and viral protection study. (A) Sedimentation profiles of purified NPfl and NPt-VP11-100 proteins were analyzed
on a 12 % SDS-PAGE gel stained with Coomassie Brilliant Blue. * indicates the fractions that were pooled and concentrated. (B) Hamster's
physiology before and after viral challenge. Arrow indicates limb paralysis. (C) Paralysis score and (D) body weight of hamsters following
challenge with EV71P5.
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systems were perhaps due to the use of the EV71P5
in the challenge studies. The mouse-adapted EV71P5
virus may not be suitable for the hamster model. It
was noted that hamsters may only get severe infec-
tions and increased mortality when higher doses of
virus, compared to the one in the present study, were
used (unpublished observation). It is known that virus
adaptation to a specific host will alter their infectivity
to other hosts. Adaptation of EV71 clinical isolate in
Chinese hamster ovary cells resulted in a reduced
virulence in newborn BALB/c mice [10]. Differences
in genetic background of hosts are also important in
viral infections [11]. Receptor specificity is another
factor which determines virus cell tropism [12].
Hence, in the present study, the use of the mouse-
adapted EV71P5 may contribute to the reduced sus-
ceptibility in the hamsters.Pre-challenge and post-challenge sera from all the
hamsters were collected and analyzed using ELISA.
When the full length VP1 was used as the coating
antigen, no IgG response was observed in the control
NPfl hamsters (Figure 2A). In contrast, a remarkable
increase (p < 0.0001) was seen in the hamster group
vaccinated with the NPt-VP11-100. After viral challenge,
both of the groups showed high titers of anti-VP1 IgG.
Similar to the results of the mouse studies [6,7], the
NPt-VP11-100 was able to induce strong immune
responses in vivo. In both the NPt-VP11-100 and the
NPfl control groups, all hamsters produced extremely
high titer of anti-NP before and after viral challenge
(Figure 2B). This observation is in agreement with pre-
vious studies which showed the highly immunogenic
nature of the NP [3,7].
To further confirm the presence of anti-VP1 and
anti-NP antibodies in all the collected sera,
Figure 2 Anti-VP1 and anti-NP IgG levels in sera before and after viral challenge. Determination of total anti-VP1 IgG antibodies (A) and
total anti-NP IgG antibodies (B). (C) Purified VP1 or NP proteins were separated on 12% SDS-PAGE gel and electro-transferred onto membranes.
Strips of the membranes were incubated with different types of sera. Arrow indicates the expected position for VP1 band. Arrowhead indicates
the expected position for NPfl band.
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against separated, purified full length VP1 and NPfl
proteins. An intense band of about 40 kDa appeared on
the VP1 membrane indicating positive detection for
anti-VP1 antibodies (Figure 2C, arrow). As observed in
the ELISA study, no band was noted in the pre-immune,
as well as the pre-challenge sera from the control
group. On the NPfl membrane, a band with approxi-
mate size of 55 kDa formed, confirming the presence
of anti-NP antibodies (Figure 2C, arrowhead). The ab-
sence of a band in the pre-immune sera corroborated
the previous ELISA findings. These results showed
that the NPt-VP11-100 was capable of inducing high
levels of immune responses in hamster. Overall, the
immunogenicity of the protein is high in rabbit [3],
mice [7] as well as hamsters.NPfl NPt-VP11-100 Post-cha
Pre-challenge  
Figure 3 Cytopathic effects in Vero cells following a neutralization te
on Vero cells. Cytopathic effects were examined after 7 days of incubation
the NPfl-immunized samples (1:8 dilution) and NPt-VP11-100-immunized sam
the positive control sera. No serum was used in the negative control sampTo investigate whether the antibodies produced were
able to neutralize EV71 virus, neutralization assay was
performed. Following seven days of incubation, CPE in
Vero cells was observed in the pre-challenged NPfl and
NPt-VP11-100 samples. Representative images of the CPE
are shown in Figure 3. In all the post-challenge sera
samples, no CPE was observed up to 1:512 titers. This
finding is in line with the results found in the mice stud-
ies [7]. The antibodies against NPt-VP11-100 produced in
mice also failed to neutralize EV71 virus despite partially
protecting the mice against a lethal viral challenge.
Results obtained in this study showed that the
NPt-VP11-100 candidate EV71 vaccine was capable of
providing excellent immune stimulation in newborn
hamsters. These data provide additional evidence that
NPt-VP11-100 is a promising EV71 vaccine candidate.Negative controlllenge  Positive control
st. Mixtures of sera dilutions and EV71 strain A104 virus were assayed
and neutralization titers were determined. Pre-challenge sera showed
ples (1:8 dilution). 1:512 dilution was used for the post-challenge and
les. Magnification= 200X.
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ster system may be used as an alternative animal
model for the efficacy testing of EV71 candidate vac-
cines. Since the lack of appropriate animal models is
one of the major hurdles for development of an
effective vaccine towards EV71 infection, our findings
will contribute towards the information needed for
finding an optimum animal model. Importantly,
the hamster system offers a prolonged susceptibility
period to EV71 infection which allows for a more
flexibility in parameter testing for vaccination and
viral challenge. To improve this hamster system, we
are currently optimizing several parameters such as
the amount of proteins used in the vaccination, the
immunization doses and intervals and the virus
strain used in the challenge experiment. Nevertheless,
these findings have paved ways towards a more com-
prehensive study of the evaluation of NPt-VP11-100
recombinant protein as a candidate EV71 vaccine in
an alternative animal model system.
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